Due to COVID-19, HCA’s lobby is closed. Learn more about your customer service options.
Become an Endorsing Practitioner
On this page
When a Washington State licensed practitioner endorses the Washington PDL and prescribes a drug for a patient, pharmacies will automatically interchange a preferred drug for any nonpreferred drug in that therapeutic class. After making the interchange, the pharmacist will notify the practitioner of the drug and dosage dispensed to the patient.
No interchange is allowed if the prescription is for a refill of a/an:
- Immunomodulator/antiviral treatment for hepatitis C for which an established, fixed duration of therapy is prescribed for at least twenty-four weeks but no more than forty-eight weeks, in which case the pharmacist shall dispense the prescribed nonpreferred drug.
As a licensed practitioner who endorses the PDL, when you prescribe a drug for a patient covered by the Department of Labor and Industries, or Uniform Medical Plan, pharmacies will automatically interchange a preferred drug for any nonpreferred drug in that therapeutic class. You can also indicate "Dispense As Written" (DAW) on a prescription and no substitution will be made. This saves prescriber time by eliminating prior authorizations for nonpreferred drugs.
How long will it take for my endorsement status to update?
Your status as an Endorsing Practitioner will take effect in five business days after submittal of the completed form. You can apply online or mail in the printable registration form.
The Pharmacy and Therapeutic (P&T) Committee evaluates the relative safety, efficacy, and effectiveness of prescription drugs within a class of drugs. They then make recommendations to the state on the development of the Washington PDL. The P&T Committee meet at least quarterly and the meetings are open to the public.
Washington State contracts with the Center for Evidence-Based Policy (Oregon EPC), Oregon Health and Science University to independently review prescription drugs comparing the safety, efficacy, and effectiveness of drug classes and providing updates every six months.